详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Fuzhou, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China

出处：

ISSN：

关键词： aumolertinib EGFR-TKI adenosquamous carcinoma

语种：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2020]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 15.609 出版当年[2020版] 14.138 出版当年五年平均 13.357 出版前一年[2019版] 20.121 出版后一年[2021版]

第一作者：

第一作者单位： [1]Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Fuzhou, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) [2]Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma [3]Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma [4]Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study [5]Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer [6]EGFR-TKI不良反应管理专家共识 [7]Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results [8]盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应 [9]Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials [10]Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases